| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 7.32 | 0.19 (+2.66%) | 5.26 - 9.56 | 221.3 thousand |
Market data as of 3:59PM 06/19/13. Quotes are delayed by at least 15 min.
| Open | 7.15 |
|---|---|
| Previous Close | 7.13 |
| Day's Range | 7.07 - 7.48 |
| Market Cap | 182.3M |
| Avg Volume (10 Day) | 231.6K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -1.37 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Cempra Prices Public Offering of Common Stock
PR Newswire - Friday 06/14/2013 9:29 AM ET
Cempra Provides Guidance on the Clinical Program Required for Regulatory Approval for Solithromycin for Community-Acquired Bacterial Pneumonia (CABP)
PR Newswire - Thursday 06/13/2013 4:02 PM ET
Cempra Announces Proposed Public Offering of Common Stock
PR Newswire - Thursday 06/13/2013 4:01 PM ET
Cempra, Inc., Announces Notification of Patent Allowance for U.S. Patent Application on Taksta Loading Dose Formulation
PR Newswire - Thursday 05/30/2013 8:00 AM ET
Cempra, Inc. to Present at Jefferies 2013 Global Healthcare Conference
PR Newswire - Wednesday 05/29/2013 4:05 PM ET
Cempra Awarded $58 Million Contract to Develop Antibiotic for Pediatric Use and Biodefense by Biomedical Advanced Research and Development Authority (BARDA)
PR Newswire - Tuesday 05/28/2013 9:15 AM ET
Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP)
PR Newswire - Monday 05/20/2013 8:00 AM ET
| CEMP | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -- | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.21 | |
| LT Debt/Equity | 0.14 | |
| Earnings Yield | -- | |
| Price/Sales | -- |
| Company | Last | Change |
|---|---|---|
| BioDelivery Sciences International Inc | 4.53 | -2.79% |
| Neptune Technologies & Bioressources Inc | 3.04 | +2.01% |
| Galena Biopharma Inc | 2.08 | 0.00% |
| Corcept Therapeutics Inc | 1.79 | -2.19% |
| Pacific Biosciences of California Inc | 2.79 | -0.36% |
Data is delayed by at least 15 min.